B

BigHat Biosciences

ML-guided antibody discovery and engineering

Overview

BigHat Biosciences designs and develops antibody therapies by combining machine learning with synthetic biology. Its Milliner platform integrates a wet-lab workflow with AI to discover, engineer, and fully characterize hundreds of recombinant antibodies each week, enabling rapid development of safer and more effective treatments for hard-to-treat diseases such as certain infections and cancers. Unlike traditional antibody discovery, Milliner provides end-to-end screening, purification, and characterization in a high-throughput, weekly workflow, speeding up the path from concept to candidate. The company differentiates itself through its integrated platform that couples ML-driven design with synthetic biology experimentation, a focus on challenging diseases, and a culture that emphasizes work-life balance. Its goal is to deliver faster, safer antibody therapies to patients by expanding access to rapid discovery and engineering capabilities for healthcare providers and patients alike.

Work here?Claim your company

About BigHat Biosciences

Simplify's Rating
Why BigHat Biosciences is rated
B-
Rated B on Competitive Edge
Rated B on Growth Potential
Rated C on Differentiation

Industries

Data & AnalyticsAI & Machine LearningBiotechnologyHealthcare

Company Size

51-200

Company Stage

Series C

Total Funding

$174.3M

Headquarters

San Mateo, CA

Founded

2019

Get referred to BigHat Biosciences

See people who can refer or advise you

Simplify Jobs

Simplify's take

What believers are saying

  • September 24, 2026 Series C raised $75 million, extending runway to clinical readouts.
  • Anthropic selected BigHat for Claude-enabled lead optimization in October 2026, boosting platform credibility.
  • Lilly TuneLab and Merck milestones deepen partner demand for BigHat's data-generation engine.

What critics are saying

  • BHB810 has no human efficacy data; Phase 1 readouts determine whether the platform matters.
  • BHB299 remains preclinical in November 2026, leaving BigHat dependent on one clinical asset.
  • If BHB810 disappoints on safety or response, BigHat becomes a services-heavy platform story.

What makes BigHat Biosciences unique

  • BigHat couples Milliner automation with frontier AI to iterate protein designs faster than rivals.
  • BHB810 entered Phase 1 on September 1, 2026, validating AI-to-clinic translation.
  • Merck completed three collaborations in August 2026, proving partnerable antibody engineering execution.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$174.3M

Above

Industry Average

Funded Over

4 Rounds

Notable Investors:
Series C funding is usually for startups that are doing well and are looking for more money to fuel major growth, such as acquiring other companies, expanding into global markets, or launching new product lines. Investors typically include larger venture capital firms and private equity.
Series C Funding Comparison
Above Average

Industry standards

$50M
$50M
$62M
$75M
$100M

Benefits

  • Professional Development Budget

Growth & Insights and Company News

6 month growth

3%

1 year growth

3%

2 year growth

-10%
AgentLensHQ
Oct 28th, 2026
Anthropic Claude Life Sciences research and drug development progress.

Anthropic Claude Life Sciences research and drug development progress. October 27, 2026 · gemini-3.1-flash-lite Accelerating drug development with AI. Anthropic's life sciences team has spent recent months partnering with six biotechnology organizations - BigHat Biosciences, Bristol Myers Squibb, Divergence Labs, Enveda, Generate Biomedicines, and The Column Group - to integrate Claude into the drug development pipeline. The goal is to address bottlenecks across the entire lifecycle of medicine creation, including target identification, molecule design, manufacturing optimization, and regulatory filing. Key case studies in ai-driven discovery. * Generate Biomedicines: Scientists used Claude to redesign a signaling domain for CAR T-cell therapy. The resulting design was 70% shorter than the standard version while increasing receptor expression by 10x, potentially enabling more effective treatment for solid tumors. * Divergence Labs: Claude autonomously generated roughly 35,000 antibody designs to target food allergies. The model identified "hits" that dislodged IgE from immune cells more effectively than current FDA-approved medications, with the entire design process taking weeks rather than months. * BigHat Biosciences: In a lead optimization project, Claude helped refine two antibody fragments. The final variants showed significant improvements in binding affinity (10x), thermostability, and resistance to clumping. Notably, Claude helped identify that standard metrics for stability were misleading, proposing new analytical methods that were validated in the lab. * Enveda: To address the 75% of time chemists spend on paperwork, Enveda built a system connecting Claude to their manufacturing records. The model successfully flagged all issues identified by human reviewers and discovered seven additional errors, reducing total human review time by 89%. * Mithril Medicine: Acquired by Anthropic, this program demonstrated a "Pipeline-in-a-Person" model. Founder Cody Tranbarger used Claude to manage logistics across 11 external labs, taking a potential treatment for muscular dystrophy from concept to promising mouse model results in under 18 months. Industry perspectives and challenges. While these results highlight the potential for AI to streamline drug development, the community has expressed a mix of optimism and caution regarding the scope of AI's impact. * The Bottleneck Debate: Many observers note that while AI can accelerate molecule design, the most significant costs and time delays occur during clinical trials. Commenters on Hacker News emphasized that biology remains highly complex and non-deterministic compared to software engineering, meaning that "moving at the speed of life" remains a fundamental constraint. * Administrative vs. Scientific Value: Some critics argue that using AI to automate paperwork is a symptom of excessive bureaucracy rather than a breakthrough in drug discovery. However, proponents suggest that freeing scientists from administrative burdens is a necessary step to increase overall research throughput. * Access and Guardrails: Researchers have noted frustration with increasingly aggressive safety guardrails in public versions of Claude, which can impede legitimate biochemical research. Anthropic has responded by launching the Life Sciences Verification Program and providing Claude credits to researchers, though some in the academic community continue to advocate for more capable, open-source models that do not impose similar usage restrictions. Future outlook. Anthropic plans to scale these efforts, moving from preclinical research into clinical trial planning. The company is actively seeking guest investigators and partners to further test the "Pipeline-in-a-Person" model, aiming to prove that AI can enable small teams to run multiple complex drug programs in parallel, thereby reducing the financial barriers to researching rare and neglected diseases.

AgentLensHQ
Oct 27th, 2026
Anthropic Early progress on accelerating drug development with Claude.

Anthropic Early progress on accelerating drug development with Claude. October 27, 2026 · Originally published October 26, 2026 · gemini-3.1-flash-lite Accelerating drug development with AI agents. Anthropic's life sciences team is actively integrating Claude into the drug development lifecycle to address bottlenecks ranging from molecular design to regulatory compliance. By partnering with six organizations - BigHat Biosciences, Bristol Myers Squibb, Divergence Labs, Enveda, Generate Biomedicines, and The Column Group - Anthropic is demonstrating that AI can function as an autonomous agent to reduce the time and cost required to bring new medicines to patients. These efforts are currently focused on preclinical research, with plans to scale operations into clinical trial planning. Key case studies and technical applications. Modality engineering: Generate Biomedicines. Generate Biomedicines utilized Claude Code to redesign the signaling domain of CAR T-cell therapy. The goal was to create a more compact receptor to enable multi-functional cancer-fighting capabilities. The resulting design was 70% shorter than the standard version and demonstrated a 10-fold increase in receptor expression on the cell surface, leading to more efficient tumor cell destruction in laboratory tests. Hit generation: Divergence Labs. To address food allergies, Divergence Labs tasked Claude with designing a bispecific antibody capable of detaching IgE from immune cells. Claude autonomously generated approximately 35,000 antibody designs over one month. Laboratory validation identified 20 "hits" capable of dislodging IgE, with three designs outperforming the standard medication, Xolair, in early tests. Lead optimization: BigHat Biosciences. BigHat Biosciences combined Claude with its automated lab system, Reccy, to optimize two antibody fragments. Over 10 weeks, the team tested 1,010 variants. Beyond design, Claude and the researchers identified that standard heat-stability metrics were misleading. By reanalyzing raw data, they developed new metrics and protocols, resulting in molecules that bound 10x more tightly and showed significantly improved stability and reduced clumping. Regulatory documentation: Enveda. Enveda implemented a system called the CMC Document Processor (CDP) to automate the review of manufacturing records. In a test involving 1,061 pages of documentation, Claude identified all 11 issues previously found by human reviewers, plus seven additional issues. This process reduced human review time by 89%, from 25 hours to less than three. Additionally, Claude drafted portions of an FDA Investigational New Drug (IND) application in four hours, a task typically taking three months by hand. Company creation: The Column Group (TCG). TCG is launching a new company, Pleiades, designed to be "AI-enabled from Day One." By using Claude to evaluate target-disease pairs, TCG has reduced the time required for initial target assessment from weeks to days. This efficiency allows for a higher volume of research programs, enabling investment in riskier, novel biological targets that were previously considered too costly to pursue. Implications for future research. Anthropic's strategy emphasizes that drug development bottlenecks are distributed throughout the entire process, not just in initial molecule design. By providing Claude credits to life scientists and launching the Life Sciences Verification Program, the company aims to lower the barrier for researchers to use powerful models in biological contexts. The ongoing work with Bristol Myers Squibb to optimize clinical trial planning marks a shift toward applying these AI capabilities to later-stage development. Anthropic's acquisition of Mithril Medicine and its "Pipeline-in-a-Person" model further suggests a future where a single researcher, supported by AI agents, can manage multiple drug discovery programs simultaneously.

DevCuration
Sep 25th, 2026
BigHat Biosciences builds an ai-native antibody engine.

BigHat Biosciences builds an ai-native antibody engine. BigHat Biosciences is building an AI-native system for designing protein therapeutics, with an unusual insistence that the software answer to the laboratory. Its platform connects frontier models to autonomous, high-throughput experiments, then feeds the resulting biological data back into the next design cycle. The San Mateo biotechnology company was founded in 2019 by Peyton Greenside and Mark DePristo. Greenside now serves as CEO, while DePristo remains a co-founder and adviser. BigHat develops wholly owned medicines and works with pharmaceutical partners on difficult antibody-engineering programs. BigHat matters now because its thesis has crossed into the clinic. Lead program BHB810 entered a Phase 1 study in 2026, a second candidate is moving through preclinical development, and a new $75M Series C brought company-reported funding to $223M. The question is no longer whether AI can propose an interesting protein. The question is whether a company can repeatedly turn designs into drug candidates with the manufacturing, safety, and clinical properties that medicine demands. How BigHat's AI and wet lab work together. BigHat's core advantage is supposed to be a learning loop, not a single model. Milliner is the company's automated experimental engine. It produces and characterizes protein variants, generating the positive and negative results that models need to improve. Reccy acts as the data-control layer, while Reccy Antibody Design Studio, or RADS, coordinates models and datasets across programs. That architecture attacks a recurring weakness in AI drug discovery: a model can generate more molecules than a traditional laboratory can reliably build, test, and learn from. BigHat designed the laboratory around the computational cycle, with standardized assays, automation, and software linking predicted properties to measured outcomes. For partners, BigHat reports one- to two-week data-generation cycles, support across major antibody formats, and more than 20 assay types. Those figures are company-reported, but they reveal the operating ambition. BigHat is trying to make biological data production behave less like a series of bespoke experiments and more like an engineered system that improves with use. The pipeline is becoming the platform's real test. BHB810 is BigHat's lead clinical program, a CDH17-directed antibody-drug conjugate for gastric cancer and other advanced gastrointestinal malignancies. BigHat announced the first patient dosed in September 2026 in a Phase 1 dose-escalation study. The company has reported encouraging preclinical findings, but no human clinical outcome data is available. The distinction matters. AI-designed medicine has spent years collecting elegant demos, promising papers, and patient investors. Clinical development is less impressed by novelty. A molecule has to show acceptable safety, measurable activity, manufacturability, and a benefit that survives contact with human biology. BHB299, an avidity-driven CEACAM6xCD3 T-cell engager for solid tumors, is BigHat's second named program. The company says it is nearing the end of preclinical development and plans to begin human studies in 2027. Additional oncology and immunology programs remain earlier or undisclosed. Partnerships add a second route to validation. BigHat's partnering strategy gives the platform another way to prove itself while its internal pipeline matures. The company has announced collaborations with Amgen, Merck, Johnson & Johnson, AbbVie, and Eli Lilly across oncology, immunology, neuroscience, and broader protein-engineering challenges. The most useful signal is completed work, not logo density. BigHat reported successful completion of a strategic J&J collaboration and three Merck project collaborations. Merck is continuing to evaluate sequences generated through those programs, and BigHat received an undisclosed milestone payment after the three projects. This hybrid model is demanding. Partner programs can generate data, revenue, and external validation, but they also compete for scientific attention with wholly owned assets. BigHat has to show that the same infrastructure can serve different molecular problems without becoming a custom-services shop wearing an AI badge. Leadership reflects a company moving into development. BigHat's current leadership spans computation, laboratory systems, drug development, and business operations. Peyton Greenside leads the company as CEO and co-founder. Stefan Weigand, formerly head of large-molecule research at Roche, is Chief Scientific Officer. John Corbin is Chief Development Officer, and Liz Schwarzbach is Chief Business Officer. The operating bench also includes Eddie Abrams as Chief Information Officer, Charbel Eid as VP of Platform, Hunter Elliott as VP of Machine Learning, Ryan Henrici as VP of Discovery Medicine, and Brett Weinstein as VP of Finance. That mix tracks the company's central burden: BigHat has to run an AI organization, an automated laboratory, a drug-discovery engine, and a clinical-stage biotech at the same time. Leadership changes also deserve precision. Mark DePristo helped found BigHat and served as its earlier CEO. Greenside is the current CEO. Treating those titles as interchangeable would make the story cleaner and the facts worse, a trade biotech has already made often enough. Hiring shows where BigHat expects pressure. BigHat's careers page listed 21 open roles on September 24, 2026. The openings spanned laboratory science, machine learning, software engineering, clinical operations, finance, and corporate systems. A time-stamped job count can change quickly, but the functional spread says more than the total. The company is staffing both sides of the loop. It needs people who can automate experiments, characterize molecules, build models, maintain data infrastructure, and move candidates through clinical development. That is a sign of execution load, not proof of commercial success. BigHat describes its culture as high-performance, collaborative, family-friendly, and patient-focused, with an emphasis on integrity and work-life balance. The real cultural test will be whether teams with radically different working rhythms can share one operating system. Machine-learning researchers iterate in code. Clinical organizations advance through documentation, controls, and decisions that cannot be hot-fixed on Friday night. What BigHat Biosciences must prove next. The September 2026 $75M Series C gives BigHat more runway to advance BHB810, prepare BHB299 for the clinic, expand its data platform, and support partnered work. It also raises the standard of proof. BigHat now has to deliver clinical readouts without confusing preclinical promise for patient benefit. It has to show that its data advantage compounds across programs, that partner successes translate into repeatable economics, and that a larger organization can preserve the speed of its design-build-test-learn loop. The company has built an impressive machine for asking biology better questions. The next chapter is about the answers: whether BigHat can turn AI, automation, and disciplined experimentation into medicines that work for patients, not just models that look smart on a slide.

HedgeCo
Sep 25th, 2026
BigHat Biosciences raised $75 million Series C co-led by DFJ Growth and Premji Invest:

BigHat Biosciences raised $75 million Series C co-led by DFJ Growth and Premji Invest: HedgeCo.Net - San Mateo-based BigHat Biosciences on September 24, 2026 announced a $75 million Series C co-led by DFJ Growth and Premji Invest, bringing total funding raised to about $223 million, according to the company's Business Wire release syndicated on BioSpace and Axios Pro Biotech coverage. Catalio Capital Management, LG Technology Ventures, Sigmas Group and existing investors including 8VC, Andreessen Horowitz, Amgen Ventures, Eli Lilly and Company, Merck Global Health Innovation Fund and Section 32 participated. Proceeds support advancement of BigHat's clinical-stage pipeline - including CDH17 ADC BHB810, which has dosed a first Phase 1 patient, and CEACAM6 T-cell engager BHB299 nearing completion of preclinical development - and growth of its AI-plus-autonomous-experimentation platform for rapid protein design. CEO and co-founder Peyton Greenside said the financing advances both the pipeline of BigHat-designed therapeutics and the data platform that powers frontier models for protein design. For protein-AI venture trackers, the hard marks are the $75 million Series C, DFJ Growth and Premji Invest co-leads, ~$223 million cumulative funding, San Mateo base, and clinical/preclinical markers for BHB810 and BHB299. Do not invent a round valuation beyond what the cited releases disclose.

The Pharma Letter
Sep 24th, 2026
BigHat Biosciences closes $75 million Series C financing.

BigHat Biosciences closes $75 million Series C financing. 24 September 2026 California, USA-based clinical-stage, AI-driven biotech BigHat Biosciences today announced the completion of a $75 million Series C financing, bringing its total funding raised to date to $223 million. The round was co-led by DFJ Growth & Premji Invest with participation from Catalio Capital Management, LG Technology Ventures, Sigmas Group, and existing investors including 8VC, Alexandria Venture Investments, Amgen (Nasdaq: AMGN), Andreessen Horowitz (a16z), Discovery Ventures, GRIDS Capital, Intermountain Ventures, Eli Lilly (NYSE: LLY), and Merck Global Health Innovation Fund, Quadrille Capital, and Section 32. This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here. Try before you buy Free. 7 day trial access * All the news that moves the needle in pharma and biotech * Exclusive features, podcasts, interviews, data analyses and commentary from its global network of life sciences reporters. * Receive The Pharma Letter daily news bulletin, free forever. Become a subscriber £820. Or £77 per month * Unfettered access to industry-leading news, commentary and analysis in pharma and biotech. * Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results. * Daily roundup of key events in pharma and biotech. * Monthly in-depth briefings on Boardroom appointments and M&A news. * Choose from a cost-effective annual package or a flexible monthly subscription The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It's part of the key information for keeping me informed Chairman, Sanofi Aventis UK More on this story... 21 July 2022 17 April 2025 9 September 2024 Company news directory. Companies featured in this story. Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news Today's issue. 24 September 2026 Company spotlight. A biotech company integrating AI and synthetic biology to design safer and more effective antibody therapeutics. More features in biotechnology. 24 September 2026

Recently Posted Jobs

Sign up to get curated job recommendations

BigHat Biosciences is Hiring for 13 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs